SCHEMBL3917152

SCHEMBL3917152

Cc1ccc(Cl)c(Cl)c1S(=O)(=O)Nc1ccc2c(c1)c(=O)[nH]n2Cc1ccc(F)c(F)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.36
PTGDR2 Q9Y5Y4 2/20 0.36
PKM P14618 5/20 0.36
SMN1; SMN2 Q16637 3/20 0.35
BRD1 O95696 1/20 0.35
BRPF1 P55201 1/20 0.35
HTT P42858 3/20 0.35
TP53 P04637 1/20 0.35
CDK1 P06493 1/20 0.35
CCNB1 P14635 1/20 0.35
CCNA2 P20248 1/20 0.35
CDK2 P24941 1/20 0.35
CDK7 P50613 1/20 0.35
CCNH P51946 1/20 0.35
CCNA1 P78396 1/20 0.35
MAPT P10636 4/20 0.35
ALDH1A1 P00352 2/20 0.35
CYP1A2 P05177 2/20 0.35
POLB P06746 2/20 0.35
CYP3A4 P08684 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3909837 0.88 PFKFB3 (0.40) LMNAPTGDR2PKMSMN1; SMN2BRD1
SCHEMBL3913835 0.85 LMNA (0.39) LMNAPTGDR2PKMSMN1; SMN2HTT
SCHEMBL3906659 0.84 PTGES2 (0.47) LMNAALDH1A1NR1I2
SCHEMBL3904603 0.83 MAPT (0.46) LMNAPTGDR2PKMSMN1; SMN2BRD1
SCHEMBL3911569 0.82 CDK1 (0.41) LMNAPTGDR2PKMHTTTP53
SCHEMBL3913785 0.82 PTGDR2 (0.48) LMNAPTGDR2PKMSMN1; SMN2BRD1
SCHEMBL3906967 0.82 PKM (0.40) LMNAPTGDR2PKMHTTCDK1
SCHEMBL3905782 0.82 GSPT1 (0.41) LMNAPKMMAPTALDH1A1CYP1A2
SCHEMBL3911615 0.82 PFKFB3 (0.40) PTGDR2PKMSMN1; SMN2TP53MAPT
SCHEMBL3917126 0.80 BRD4 (0.49) LMNAPKMMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7528158-B2 Indazolone derivatives useful as 11b-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US disclosed
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2006-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors HSD17B1, HSD11B1, HSD17B7 LMNA 3419/4885PTGDR2 925/4885PKM 1481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.